Staging the Host: Personalizing Risk Assessment for Radical Cystectomy Patients

Sarah P. Psutka(University of Washington Medical Center), Stephen A. Boorjian(Mayo Clinic), Todd M. Morgan(University of Michigan), James W.F. Catto(University of Sheffield), Cheryl T. Lee(The Ohio State University Wexner Medical Center), John L. Gore(University of Washington), Daniel A. Barocas(Vanderbilt University Medical Center), Andrea Necchi(Vita-Salute San Raffaele University), Morgan Rouprêt(Sorbonne Université), Viraj A. Master(Emory University)
European Urology Oncology
June 19, 2018
10.1016/j.euo.2018.05.010
Cited by 67

Related Papers

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|3.7k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|2.2k
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
|The Lancet Oncology|2017|1.8k
Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label, randomised, phase 3, non-inferiority trial
|The Lancet|2018|779